Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
porustobart (HBM4003)
i
Other names:
HBM4003, HBM 4003, HBM-4003
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Harbour BioMed
Drug class:
CTLA4 inhibitor, Treg cell depleter
Related drugs:
‹
ipilimumab (223)
tremelimumab (60)
KN046 (19)
cadonilimab (10)
PSB205 (3)
ipilimumab biosimilar (CS1002) (2)
MK-1308 (2)
GI-101 (1)
XTX101 (1)
BNT316 (1)
MEDI5752 (1)
XmAb717 (1)
AI-061 (0)
ATOR-1015 (0)
BMS-986218 (0)
BMS-986249 (0)
BMS-986288 (0)
BT-001 (0)
CD200AR-L (0)
IBI310 (ipilimumab biosimilar) (0)
IMM27M (0)
INV322 (0)
KD6001 (0)
MT-8421 (0)
prolgolimab/nurulimab (0)
ONCR-177 (0)
PF-06753512 (0)
RP2 (0)
RP3 (0)
SAL008 (0)
SHR-8068 (0)
TG6050 (0)
YH001 (0)
XmAb22841 (0)
SI-B003 (0)
MGD019 (0)
ADG126 (0)
MK-1308A (0)
ALD2510 (0)
ipilimumab (223)
tremelimumab (60)
KN046 (19)
cadonilimab (10)
PSB205 (3)
ipilimumab biosimilar (CS1002) (2)
MK-1308 (2)
GI-101 (1)
XTX101 (1)
BNT316 (1)
MEDI5752 (1)
XmAb717 (1)
AI-061 (0)
ATOR-1015 (0)
BMS-986218 (0)
BMS-986249 (0)
BMS-986288 (0)
BT-001 (0)
CD200AR-L (0)
IBI310 (ipilimumab biosimilar) (0)
IMM27M (0)
INV322 (0)
KD6001 (0)
MT-8421 (0)
prolgolimab/nurulimab (0)
ONCR-177 (0)
PF-06753512 (0)
RP2 (0)
RP3 (0)
SAL008 (0)
SHR-8068 (0)
TG6050 (0)
YH001 (0)
XmAb22841 (0)
SI-B003 (0)
MGD019 (0)
ADG126 (0)
MK-1308A (0)
ALD2510 (0)
›
Associations
News
Trials
Filter by
Latest
1year
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=65, Completed, Harbour BioMed US, Inc. | Active, not recruiting --> Completed | Trial primary completion date: Sep 2022 --> Jan 2023
1 year ago
Trial completion • Trial primary completion date • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
porustobart (HBM4003)
almost2years
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=65, Active, not recruiting, Harbour BioMed US, Inc. | Trial primary completion date: Jun 2022 --> Sep 2022
almost 2 years ago
Trial primary completion date
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
porustobart (HBM4003)
2years
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=65, Active, not recruiting, Harbour BioMed US, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2023 --> Jun 2022
2 years ago
Enrollment closed • Trial primary completion date
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
porustobart (HBM4003)
almost3years
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=52, Recruiting, Harbour BioMed US, Inc. | N=30 --> 52 | Trial completion date: Feb 2022 --> Mar 2023 | Trial primary completion date: Oct 2020 --> Mar 2023
almost 3 years ago
Clinical • Enrollment change • Trial completion date • Trial primary completion date
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
porustobart (HBM4003)
3years
A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody (clinicaltrials.gov)
P1, N=66, Not yet recruiting, Harbour BioMed (Guangzhou) Co. Ltd.
3 years ago
Clinical • New P1 trial • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • porustobart (HBM4003)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login